These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22328017)

  • 1. Genetic mechanisms of chronic myeloid leukemia blastic transformation.
    Skorski T
    Curr Hematol Malig Rep; 2012 Jun; 7(2):87-93. PubMed ID: 22328017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukemia: mechanisms of blastic transformation.
    Perrotti D; Jamieson C; Goldman J; Skorski T
    J Clin Invest; 2010 Jul; 120(7):2254-64. PubMed ID: 20592475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.
    Skorski T
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1(0 1):23-9. PubMed ID: 21299457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
    Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
    Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic events other than BCR-ABL1.
    Neviani P
    Curr Hematol Malig Rep; 2014 Mar; 9(1):24-32. PubMed ID: 24407376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosing and managing advanced chronic myeloid leukemia.
    Deininger MW
    Am Soc Clin Oncol Educ Book; 2015; ():e381-8. PubMed ID: 25993200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genomic Instability in Acute Transformation of Chronic Myelogenous Leukemia].
    Guo SQ; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1199-202. PubMed ID: 26314473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
    Huang R; Kang Q; Liu H; Li Y
    Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.
    Slupianek A; Falinski R; Znojek P; Stoklosa T; Flis S; Doneddu V; Pytel D; Synowiec E; Blasiak J; Bellacosa A; Skorski T
    Leukemia; 2013 Mar; 27(3):629-34. PubMed ID: 23047475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
    Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
    Bavaro L; Martelli M; Cavo M; Soverini S
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chronic myeloid leukemia stem cell: stemming the tide of persistence.
    Holyoake TL; Vetrie D
    Blood; 2017 Mar; 129(12):1595-1606. PubMed ID: 28159740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.